T6293

Mycophenolate Mofetil (TM-MMF), an immunosuppressive agent, is the 2-morpholinoethyl ester of mycophenolic acid (MPA), and an inhibitor of inosine monophosphate dehydrogenase (IMPDH).

GT-055 (LCB18-055) is a novel inhibitor of broad-spectrum β-lactamase.

Antiangiogenic agent 2 (compound 3b) is a potent thymidine phosphorylase inhibitor (IC50: 39.71 μM) with demonstrated anti-angiogenic effects.

NS2B/NS3-IN-2 is a potent, covalent inhibitor of dengue virus (DENV) NS2B/NS3 with an IC50 of 6.0 nM and a Ki of 0.66 μM. It significantly increases cell viability and exhibits no cytotoxicity.

ERK1/2 inhibitor 7 is a potent inhibitor of ERK, with an IC50 of 0.94 nM for ERK2.

ZLHQ-5f is a dual inhibitor of CDK2 and Topo I, acting on CDK2/CycA2 (IC50: 0.145 μM). ZLHQ-5f has a good safety profile by blocking the cell cycle of HCT116 cells in S phase and inducing apoptosis.

Anticancer agent 26 is a promising candidate for cancer therapy and deserves further development.

Antimalarial agent 8 (Compound 7e) is a novel, orally active antimalarial effective against P. falciparum in vitro and in vivo in a mouse model of malaria at 40 mg/kg.

MAGLi 432 is a potent, highly selective, non-covalent, reversible (MAGL) inhibitor that binds with high affinity to the MAGL active site, with IC50 values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme), MAGLi 432 can be used to study neurological disorders such as chronic inflammation, multiple sclerosis, blood-brain barrier dysfunction, Alzheimer's disease and Parkinson's disease.

GNE-617 hydrochloride is a selective inhibitor of NAMPT, effectively inhibiting NAMPT activity with an IC50 of 5 nM.

SHR2415 is a selective, potent, orally active inhibitor of ERK1/2. SHR2415 inhibits ERK1 (IC50: 2.8 nM) and ERK2 (IC50: 5.9 nM). SHR2415 exhibits high potency in Colo205 cells (IC50: 44.6 nM). SHR2415 can be used in cancer research.